Evidence map›Paper›PMID 38286131›Full record

ArticleThe Lancet. Microbe2024

SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis.

Zoe Raglow, Diya Surie, James D Chappell, Yuwei Zhu, Emily T Martin, Jennie H Kwon, Anne E Frosch, Amira Mohamed, Julie Gilbert, Emily E Bendall and 17 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in The Lancet. Microbe, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 2 pooled it
31.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Is early combination therapy associated with lower risk of respiratory failure in severely immunocompromised hosts with COVID-19? a target trial emulation study from the omicron-dominant era.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  6. Is early combination therapy associated with lower risk of respiratory failure in severely immunocompromised hosts with COVID-19? a target trial emulation study from the omicron-dominant era.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Cancer and COVID-19: A review of immune insights and partnerships to inform public health strategy.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 1 country.

Zoe RaglowDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Diya SurieNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
James D ChappellDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
Yuwei ZhuDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Emily T MartinSchool of Public Health, University of Michigan, Ann Arbor, MI, USA.
Jennie H KwonDepartment of Medicine, Washington University, St Louis, MO, USA.
Anne E FroschDepartment of Medicine, Hennepin County Medical Center, Minneapolis, MN, USA.
Amira MohamedDepartment of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Julie GilbertDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Emily E BendallDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Auden BahrComputational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.
Natasha HalasaDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
H Keipp TalbotDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Health Policy, Vanderbilt University Medical Center, Nashville, TN, USA.
Carlos G GrijalvaDepartment of Health Policy, Vanderbilt University Medical Center, Nashville, TN, USA.
Adrienne BaughmanDepartment of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Kelsey N WomackVanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA.
Cassandra JohnsonDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Sydney A SwanDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Emilia KoumansDivision of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Meredith L McMorrowNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Jennifer L HarcourtNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Lydia J AthertonNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Ashley BurroughsNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Natalie J ThornburgNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Wesley H SelfDepartment of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA.
Adam S LauringDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA; Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA. Electronic address: alauring@med.umich.edu.
Investigating Respiratory Viruses in the Acutely Ill (IVY) Network
Vanderbilt University Medical Center · USCenters for Disease Control and Prevention · USUniversity of Michigan · USAlbert Einstein College of Medicine · USHennepin County Medical Center · USWashington University in St. Louis · US

Funding

PULMONARY CELLULAR AND MOLECULAR BIOLOGY TRAININGT32HL007749 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Robert Pickett Dickson · 1993 to 2026
$19.9M
Memory T follicular helper cell kinetics and localization during recall immune responses to tetanus vaccinationK08AI141761 · NIAID · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI FROSCH, ANNE ELIZABETH PARKER · 2019 to 2023
$984k
NHLBI NIH HHS T32 HL007749NIAID NIH HHS K08 AI141761
6 · The paper itself

Abstract

backgroundProlonged SARS-CoV-2 infections in people who are immunocompromised might predict or source the emergence of highly mutated variants. The types of immunosuppression placing patients at highest risk for prolonged infection have not been systematically investigated. We aimed to assess risk factors for prolonged SARS-CoV-2 infection and associated intrahost evolution.

methodsIn this multicentre, prospective analysis, participants were enrolled at five US medical centres. Eligible patients were aged 18 years or older, were SARS-CoV-2-positive in the previous 14 days, and had a moderately or severely immunocompromising condition or treatment. Nasal specimens were tested by real-time RT-PCR every 2-4 weeks until negative in consecutive specimens. Positive specimens underwent viral culture and whole genome sequencing. A Cox proportional hazards model was used to assess factors associated with duration of infection.

findingsFrom April 11, 2022, to Oct 1, 2022, 156 patients began the enrolment process, of whom 150 were enrolled and included in the analyses. Participants had B-cell malignancy or anti-B-cell therapy (n=18), solid organ transplantation or haematopoietic stem-cell transplantation (HSCT; n=59), AIDS (n=5), non-B-cell malignancy (n=23), and autoimmune or autoinflammatory conditions (n=45). 38 (25%) participants were real-time RT-PCR-positive and 12 (8%) were culture-positive 21 days or longer after initial SARS-CoV-2 detection or illness onset. Compared with the group with autoimmune or autoinflammatory conditions, patients with B-cell dysfunction (adjusted hazard ratio 0·32 [95% CI 0·15-0·64]), solid organ transplantation or HSCT (0·60 [0·38-0·94]), and AIDS (0·28 [0·08-1·00]) had longer duration of infection, defined as time to last positive real-time RT-PCR test. There was no significant difference in the non-B-cell malignancy group (0·58 [0·31-1·09]). Consensus de novo spike mutations were identified in five individuals who were real-time RT-PCR-positive longer than 56 days; 14 (61%) of 23 were in the receptor-binding domain. Mutations shared by multiple individuals were rare (<5%) in global circulation.

interpretationIn this cohort, prolonged replication-competent omicron SARS-CoV-2 infections were uncommon. Within-host evolutionary rates were similar across patients, but individuals with infections lasting longer than 56 days accumulated spike mutations, which were distinct from those seen globally. Populations at high risk should be targeted for repeated testing and treatment and monitored for the emergence of antiviral resistance.

fundingUS Centers for Disease Control and Prevention.

Indexed as

Acquired Immunodeficiency SyndromeCOVID-19NeoplasmsB-LymphocytesHumansProspective StudiesSARS-CoV-2United States

Identifiers

PMID38286131
PMCPMC11849777
OpenAlexW4391256820

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.